| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.01 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.096 | 0.02 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.02 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.02 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.096 | 0.02 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.02 |